Quantcast
Last updated on April 23, 2014 at 1:22 EDT

Latest Genmab Stories

2014-04-17 16:27:38

LONDON, April 17, 2014 /PRNewswire/ -- GlaxoSmithKline plc (LSE: GSK) and Genmab A/S (OMX: GEN) announced today that the U.S. Food and Drug Administration (FDA) has approved a Supplemental Biologic License Application (sBLA) for the use of Arzerra(®) (ofatumumab), a CD20-directed cytolytic monoclonal antibody, in combination with chlorambucil for the treatment of previously untreated patients with chronic lymphocytic leukaemia (CLL) for whom fludarabine-based therapy is considered...

2014-04-03 12:28:49

TUCSON, Ariz., April 3, 2014 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, today announced that it has entered into an agreement with Genmab A/S, Copenhagen, Denmark for the development of companion diagnostic tools for Genmab's HuMax-TF®-ADC antibody drug conjugate (ADC) program. As part of the agreement, Ventana will provide its expertise and services towards the development of an immunohistochemistry (IHC) companion diagnostic test for the...

2014-04-03 08:21:56

DUBLIN, Apr. 03, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/zvzsf4/antibodydrug ) has announced the addition of the "Antibody-Drug Conjugates 2014 - a Business, Technology & Pipeline Analysis" report to their offering. (Logo:http://photos.prnewswire.com/prnh/20130307/600769) The report entitled 'Antibody-Drug Conjugates 2014 - A Business, Technology & Pipeline Analysis' is based on the evaluation of more than 90 companies. The report...

2014-03-13 16:27:58

DUBLIN, March 13, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/43nvqj/cancer_monoclonal) has announced the addition of the "Cancer Monoclonal Antibodies Market Forecast to 2017" [http://www.researchandmarkets.com/research/43nvqj/cancer_monoclonal ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Cancer, one of the leading causes of death worldwide, affected approximately 13 Million...

2014-01-29 16:28:33

DUBLIN, January 29, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/ztm9m5/antibodydrug) has announced the addition of the "Antibody-Drug Conjugates 2014 - a Business, Technology & Pipeline Analysis" [http://www.researchandmarkets.com/research/ztm9m5/antibodydrug ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The report entitled 'Antibody-Drug Conjugates 2014 - A Business,...

2013-08-26 23:18:26

Transparency Market Research adds new "Antibody Drugs Market - Global Forecast, Market Share, Size, Growth And Industry Analysis, 2012 - 2018" market research report to its report store. Browse report at http://www.transparencymarketresearch.com/antibody-drugs.html. Albany, New York (PRWEB) August 26, 2013 Antibody drugs make use of the body’s own immune system to locate and eliminate cells which are responsible for the target disease. Antibody drugs have been successful in...

2013-07-01 12:25:20

DUBLIN, July 1, 2013 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/zrbgqj/monoclonal) has announced the addition of the "Monoclonal Antibodies Market in Rheumatoid Arthritis to 2018 - Market Characterized by Large and Diversified Pipeline and Low Threat of Biosimilar Sales Erosion" [http://www.researchandmarkets.com/research/zrbgqj/monoclonal ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )...

2013-06-06 08:26:20

DUBLIN, June 6, 2013 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/272vtc/monoclonal ) has announced the addition of the "Monoclonal Antibodies Market in Rheumatoid Arthritis to 2018 - Market Characterized by Large and Diversified Pipeline and Low Threat of Biosimilar Sales Erosion" [http://www.researchandmarkets.com/research/272vtc/monoclonal ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )...

2013-05-01 12:28:45

Second Janssen oncology compound to receive Breakthrough Therapy Designation RARITAN, N.J., May 1, 2013 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for daratumumab for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), or who are double...

2013-03-19 12:27:33

NEW YORK, LONDON, BERLIN, PARIS, March 19, 2013 /PRNewswire/ -- The currently marketed monoclonal antibodies are clinically and commercially highly successful products in the rheumatoid arthritis market [http://www.reportstack.com/product/99233/monoclonal-antibodies-market-in-rheumatoid-arthritis-to-2018-market-characterized-by-large-and-diversified-pipeline-and-low-threat-of-biosimilar-sales-erosion.html ] , constituting four of the global top 20 best-selling drugs. The...